LightInTheBox Reports Fourth Quarter and Full Year 2024 Financial Results
SINGAPORE, March 25, 2025 /PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE: LITB) ("LightInTheBox" or the "Company"), a global specialty retailer focusing on proprietary apparel brands and design-driven collections tailored to evolving consumer...
ANO-NE Kids Club to Open in Ginza, Japan on April 1: Safe "Playcation" for Kids, Carefree Time for Parents
TOKYO, March 25, 2025 /PRNewswire/ -- ANO-NE Kids Club, an innovative indoor play facility providing short-term childcare, will open in Tokyo's Ginza district on April 1, 2025. Developed by Cosmos Hotel Management Co., Ltd. and COSMOS INITIA Co.,...
FOR SALE BY EXPRESSION OF INTEREST: FREEHOLD CONSERVATION SHOPHOUSE WITH RARE F&B APPROVAL AT 350/350A TANJONG KATONG ROAD
SINGAPORE, March 25, 2025 /PRNewswire/ -- Brilliance Capital Pte. Ltd. is pleased to present an exceptional opportunity to acquire a freehold conservation two-storey shophouse with an attic at 350/350A Tanjong Katong Road. This rare offering is...
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen...
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has...
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China
SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity...
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial...
Hyundai Capital Australia Obtains Its First Credit Rating of 'A-' from S&P Global Ratings
SEOUL, South Korea, March 24, 2025 /PRNewswire/ -- Hyundai Capital Services ("Hyundai Capital" or the "Company") announced today that its 12th financial subsidiary, Hyundai Capital Australia Pty. Ltd. ("HCAU"), obtained its inaugural credit rating...
Pop Culture Group Co., Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
XIAMEN, China, March 21, 2025 /PRNewswire/ -- Pop Culture Group Co., Ltd ("Pop Culture" or the "Company") (Nasdaq: CPOP), a hip-hop culture company headquartered in China, today announced that the Company received a notification letter (the...
China Yuchai Subsidiary Adopts Equity Incentive Plan
SINGAPORE, March 21, 2025 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD) ("China Yuchai" or the "Company") one of the largest powertrain solution manufacturers through its main operating subsidiary in China, Guangxi Yuchai Machinery...